Agentless security for untouchable IoT devices

Tern plc

The rapid expansion of connected devices across enterprise and industrial environments presents a pressing security challenge for organisations preparing for 2026 and beyond. Increasingly, a large portion of a company’s device estate cannot be secured through traditional software agents or conventional update mechanisms. Many sensors, embedded controllers, medical instruments and legacy systems are either incapable of running additional software, cannot tolerate downtime for patching, or are geographically dispersed in remote or hostile environments.

Conventional endpoint security, built on the assumption that every device can host a monitoring agent, struggles at scale in environments where devices are resource constrained or run proprietary firmware. Attempting to retrofit traditional security tools often results in blind spots across thousands of device types from hundreds of vendors, increasing attack surface and operational complexity.

Agentless IoT security reframes this problem by decoupling protection from the devices themselves. Instead of installing security software on each endpoint, agentless solutions observe devices from the outside. They use network traffic analysis, infrastructure logs and application interfaces to discover and classify every IP‑connected device. By doing so, organisations gain visibility into assets they did not even know existed. This inventory of devices and behaviours becomes the foundation for identity‑based controls and policy enforcement that can be applied without touching the device itself.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search